Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

2(28.6%)

Phase 3

2(28.6%)

7Total

Phase 1(3)

Phase 2(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05263999Phase 3Terminated

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Role: lead

NCT04128579Phase 1Completed

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

Role: lead

NCT03763318Phase 1Completed

A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD

Role: lead

NCT04007198Phase 1Completed

A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma

Role: lead

NCT05589610Phase 2Completed

Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata

Role: lead

NCT03532958Phase 2Withdrawn

Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

Role: lead

NCT04605926Phase 3Withdrawn

A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

Role: lead

All 7 trials loaded